US · NVAX · BIOTECHNOLOGY
Novavax, Inc. (NVAX) intrinsic value and stock valuation
$7.47as of 2026-11-21 · Mkt cap 1.27B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Novavax, Inc. DCF and intrinsic value
InvestorsCraft values NVAX with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from NVAX’s statements →
Novavax, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.12B | $682.2M | $556.4M | $1.6B | $197.6M |
| Operating income | $563.3M | -$-248.93M | -$-566.51M | -$-644.74M | -$-1.69B |
| Net income | $440.3M | -$-187.5M | -$-545.06M | -$-657.94M | -$-1.74B |
| EPSd | $2.54M | -$-1.23M | -$-5.41M | -$-8.42M | -$-23.44M |
| Operating cash flow | -$-244.63M | -$-87.26M | -$-713.97M | -$-415.94M | $323M |
| Capital expenditure | -$-5.56M | -$-13.06M | -$-58.81M | -$-92.98M | -$-57.49M |
| Free cash flow | -$-250.19M | -$-100.32M | -$-772.77M | -$-508.92M | $265.5M |
| Total assets | $1.18B | $1.56B | $1.8B | $2.26B | $2.58B |
| Total debt | $248.8M | $230.4M | $229.1M | $549.8M | $454M |
| Net debt | $8.18M | -$-299.81M | -$-339.42M | -$-787.1M | -$-1.06B |
| Total equity | -$-127.75M | -$-623.84M | -$-716.93M | -$-634.08M | -$-351.67M |
| Cash and short-term investments | $735.1M | $923.1M | $568.5M | $1.34B | $1.52B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.12B | $682.2M | $556.4M | $1.6B | $197.6M |
| Cost of revenue | $71.1M | $202.7M | $343.8M | $902.6M | $0.00 |
| Gross profit | $1.05B | $479.4M | $212.6M | $696.3M | $197.6M |
| Research and development expenses | $336.8M | $391.2M | $737.5M | $1.24B | $2.53B |
| Selling, general and administrative expenses | $150.4M | $337.2M | $469M | $488.7M | $298.4M |
| Other expenses | $1.9M | $0.00 | -$-427.32M | -$-382.92M | -$-948.71M |
| Operating expenses | $489.1M | $728.4M | $779.1M | $1.34B | $1.88B |
| Cost and expenses | $560.2M | $931.1M | $1.12B | $2.24B | $1.88B |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $22.6M | $20.1M | $14.4M | $19.9M | $21.1M |
| Depreciation and amortization | $27.6M | $48.5M | $41.2M | $29.1M | $12.7M |
| Ebitda | $492.3M | -$-108.04M | -$-487.39M | -$-604.71M | -$-1.68B |
| Operating income | $563.3M | -$-248.93M | -$-566.51M | -$-644.74M | -$-1.69B |
| Total other income/expenses, net | -$-121.1M | $72.3M | $23.5M | -$-8.91M | -$-27.96M |
| Income before tax | $442.2M | -$-176.62M | -$-543.03M | -$-653.65M | -$-1.71B |
| Income tax expense | $1.86M | $10.9M | $2.03M | $4.29M | $29.2M |
| Net income | $440.3M | -$-187.5M | -$-545.06M | -$-657.94M | -$-1.74B |
| Weighted average shares outstanding | $162M | $152.2M | $100.8M | $78.2M | $74.4M |
| Weighted average diluted shares outstanding | $173.1M | $152.2M | $100.8M | $78.2M | $74.4M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $735.1M | $923.1M | $568.5M | $1.34B | $1.52B |
| Net receivables | $106.5M | $108.3M | $297.2M | $82.4M | $455M |
| Inventory | $11.5M | $8.75M | $41.7M | $36.7M | $8.87M |
| Total current assets | $978.3M | $1.13B | $1.14B | $1.7B | $2.16B |
| Property, plant and equipment, net | $67.7M | $300M | $491M | $400.5M | $228.7M |
| Goodwill and intangible assets | $113.5M | $107.5M | $127.5M | $126.3M | $136.3M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $1.66M | $1.65M |
| Total non-current assets | $198.2M | $431.5M | $653.6M | $555.3M | $421.6M |
| Total assets | $1.18B | $1.56B | $1.8B | $2.26B | $2.58B |
| Accounts payable | $24.6M | $41.6M | $132.6M | $216.5M | $127.1M |
| Short-term debt | $2.51M | $7.01M | $5.14M | $352.1M | $130.5M |
| Deferred revenue | $140.1M | $675.1M | $241.3M | $370.1M | $1.42B |
| Total current liabilities | $460M | $1.15B | $1.64B | $2.46B | $2.39B |
| Long-term debt | $246.3M | $223.4M | $223.9M | $197.7M | $323.5M |
| Deferred revenue, non-current | $358.9M | $446.8M | $622.2M | $179.4M | $172.5M |
| Total non-current liabilities | $844.3M | $1.03B | $879.3M | $432.8M | $538.1M |
| Capital lease obligations | $4.6M | $60.7M | $61.1M | $58.4M | $130.5M |
| Total liabilities | $1.3B | $2.18B | $2.51B | $2.89B | $2.93B |
| Common stock | $1.65M | $1.62M | $1.41M | $870K | $760K |
| Retained earnings | -$-4.57B | -$-5.01B | -$-4.82B | -$-4.28B | -$-3.62B |
| Accumulated other comprehensive income (loss) | $2.01M | -$-22.56M | $2.72M | -$-6.38M | -$-1.35M |
| Total equity | -$-127.75M | -$-623.84M | -$-716.93M | -$-634.08M | -$-351.67M |
| Total investments | $494.5M | $392.9M | $0.00 | $1.66M | $1.65M |
| Total debt | $248.8M | $230.4M | $229.1M | $549.8M | $454M |
| Net debt | $8.18M | -$-299.81M | -$-339.42M | -$-787.1M | -$-1.06B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $440.3M | -$-187.5M | -$-545.06M | -$-657.94M | -$-1.74B |
| Depreciation and amortization | $27.6M | $48.5M | $41.2M | $29.1M | $12.7M |
| Stock-based compensation | $36M | $48.2M | $85.4M | $130.3M | $183.6M |
| Change in working capital | -$-887.71M | $48.5M | -$-376.84M | -$-361.15M | $1.73B |
| Accounts receivable | $61M | $354.1M | -$-274.44M | $249.2M | -$-192.26M |
| Inventory | -$-3.24M | $12.9M | -$-74.46M | -$-477.8M | -$-600.33M |
| Accounts payable | -$-322.57M | -$-385.63M | -$-378.81M | $913.4M | $600.3M |
| Net cash provided by operating activities | -$-244.63M | -$-87.26M | -$-713.97M | -$-415.94M | $323M |
| Investments in property, plant and equipment | -$-5.56M | -$-14.64M | -$-58.81M | -$-92.98M | -$-57.49M |
| Acquisitions, net | $0.00 | $192.6M | $0.00 | $0.00 | $57.5M |
| Net cash used for investing activities | -$-78.27M | -$-204.04M | -$-58.81M | -$-92.98M | $100.2M |
| Common stock issued | $0.00 | $263.3M | $360.2M | $249.2M | $564.9M |
| Common stock repurchased | -$-4.8M | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $27.7M | $260.6M | $4.47M | $325M | $461.7M |
| Net change in cash | -$-289.24M | -$-38.52M | -$-765.03M | -$-179.41M | $879.5M |
| Cash at end of period | $256.1M | $545.3M | $583.8M | $1.35B | $1.53B |
| Operating cash flow | -$-244.63M | -$-87.26M | -$-713.97M | -$-415.94M | $323M |
| Capital expenditure | -$-5.56M | -$-13.06M | -$-58.81M | -$-92.98M | -$-57.49M |
| Free cash flow | -$-250.19M | -$-100.32M | -$-772.77M | -$-508.92M | $265.5M |
Line items
Line items
Line items
About Novavax, Inc.
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
- CEO
- John Charles Jacobs
- Employees
- 749
- Beta
- 2.43
Explore
Frequently asked questions
What is the intrinsic value of Novavax, Inc. (NVAX)?
Novavax, Inc. (NVAX) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is NVAX undervalued?
NVAX trades at a price of $7.47 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.